Pfizer Inc
PFENYSEPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 28, 2026Last filing: 10-Q on Aug 4, 2026Score 11/3053% above fair value
$30.52+0.57 (+1.90%)
Close on Oct 30, 2026Market cap $173.95BP/E 40.2Yield 5.64%
Pfizer Talzenna (talazoparib by Quarter
Talzenna (talazoparib — PARP inhibitor) — Worldwide operational (constant-currency) YoY (%) (%)
Pfizer Talzenna (talazoparib: 23.0% in Q2 2026, down 20.0 pts from a year earlier.
Latest, Q2 2026
23.0%
Period ended Jun 28, 2026
Change on a year earlier
-20.0 pts
43.0% in Q2 2025
History
8 quarters
Since Q3 2024
Sources
8
Documents cited below
Where the Q2 2026 figure comes from
“|| Talzenna | 57 | 46 | 24% | 23% | 40 | 34 | 17% | 17 | 12 | 46% | 41%”
Source: Form 8-K (Earnings / Guidance Release) (pfe-6282026xex99.htm, filed 2026-08-04) ↗
Reported in Form 8-K Revenue Tables.
Quarterly history
Hover a value to see the sentence it was read from; calculated values show their formula
Cite this data
StockData. (2026). Pfizer Talzenna (talazoparib (%), quarterly Q3 2024–Q2 2026 [Data set]. Compiled from Pfizer SEC filings and investor materials. https://stockdatahq.com/stocks/pfe/kpis/talzenna-oper-ww
See every metric in the Pfizer KPI table. Data updated Nov 2, 2026.